EUR 436,72
Anzahl: 15 verfügbar
In den WarenkorbHRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
EUR 454,51
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
EUR 491,37
Anzahl: Mehr als 20 verfügbar
In den WarenkorbGebunden. Zustand: New. Drugs are being developed to alleviate the symptoms of dementia and different models of care are being tried. This book is a reference work in the subject. It gives a basis of the disease, its epidemiology, care implications, development and use of drugs.
EUR 570,00
Anzahl: 3 verfügbar
In den WarenkorbZustand: New. pp. 596.
EUR 676,27
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 1st edition. 576 pages. 9.50x6.50x1.50 inches. In Stock.
EUR 723,18
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Drugs are being developed to alleviate the symptoms of dementia and different models of care are being tried. This book is a reference work in the subject. It gives a basis of the disease, its epidemiology, care implications, development and use of drugs. Editor(s): Winblad, Bengt; etc.; Wimo, Anders; Johnsson, Bengt (School of Health Economics, Bergjo, Sweden); Karlsonn, Goran (School of Health Economics, Bergjo, Sweden). Num Pages: 592 pages, forms. BIC Classification: MBP; MMH. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 245 x 168 x 36. Weight in Grams: 966. . 1998. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.
Buch. Zustand: Neu. Neuware - The prevalence of dementia increases greatly with age so, with increasing numbers surviving to old age, Alzheimer's disease has reached epidemic proportions, and this trend will increase in the future. The disease is therefore having a significant effect on escalating health care costs. Meanwhile, drugs are being developed to alleviate the symptoms of dementia and different models of care are being tried out. All these factors have important cost implications but it has been difficult to draw any consistent conclusions from studies so far. This book will become the standard reference work in the subject. It provides a sound introduction to the disease, its epidemiology, care implications, and the development and use of drugs. It discusses the challenges of obtaining reliable data, and reviews the tools used to assess the outcomes and costs of dementia to date. It also deals with the pharmacoeconomics of the disease, making it essential reading for all those who work with patients with dementia as well as for professionals in the pharmaceutical industry. This volume is: